Primary prevention of coronary heart disease with aspirin

被引:0
|
作者
Kübler, W [1 ]
Darius, H [1 ]
机构
[1] Vivantes Netzwerk Gesundheit, Med Klin 1, Klinikum Neukolln, D-12313 Berlin, Germany
来源
关键词
primary prevention; aspirin; risk stratification; cost effectiveness; aspirin paradox and resistance;
D O I
10.1007/s00392-005-1309-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
According to meta-analysis and the results of the two studies with the highest power, aspirin is effective in primary prevention of coronary heart disease. These beneficial effects, however, are at least partially outweight by unwanted effects - such as intense gastrointestinal bleeding and hemorrhagic stroke. These side effects remain constant with increasing risk of coronary heart disease, whereas the protective effects increase. If an annual risk of coronary heart disease of <= 0.6% exists, aspirin is normally not indicated; for a risk of 0.7-1.4% the facts should be discussed with the patient. If a risk of >= 1.5% exists, aspirin should be given. Problems of aspirin therapy such as "aspirin paradox" and "aspirin resistance" - have been documented for secondary prevention; they might, however, have likewise clinical implications in primary prevention.
引用
收藏
页码:66 / 73
页数:8
相关论文
共 50 条
  • [1] Primary prevention of coronary heart disease with aspirin
    Kübler, W
    [J]. ZEITSCHRIFT FUR KARDIOLOGIE, 2004, 93 : 33 - 36
  • [2] Aspirin under fire: Aspirin use in the primary prevention of coronary heart disease
    Miller, MG
    Lucas, D
    Papademetriou, V
    Elhabyan, AK
    [J]. PHARMACOTHERAPY, 2005, 25 (06): : 847 - 861
  • [3] Aspirin use for the primary prevention of coronary heart disease in older adults
    Rodondi, Nicolas
    Vittinghoff, Eric
    Cornuz, Jacques
    Butler, Javed
    Ding, Jingzhong
    Satterfield, Suzanne
    Newman, Anne B.
    Harris, Tamara B.
    Hulley, Stephen B.
    Bauer, Douglas C.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2005, 118 (11): : 1288.e1 - 1288.e9
  • [4] Cost-effectiveness of aspirin for the primary prevention of coronary heart disease
    Rodondi, Nicolas
    Moran, Andrew
    Coxson, Pamela G.
    Lightwood, James
    Williams, Lawrence W.
    Cornuz, Jacques
    Goldman, Lee
    [J]. CIRCULATION, 2006, 114 (18) : 827 - 827
  • [5] ASPIRIN IN THE PREVENTION OF ATHEROTHROMBOSIS AND CORONARY HEART DISEASE
    Bubnova, M. G.
    [J]. RUSSIAN JOURNAL OF CARDIOLOGY, 2010, (04): : 115 - 121
  • [6] Primary prevention of coronary artery disease by aspirin
    Taylor, Jennifer
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (08) : 467 - 468
  • [7] Aspirin for Primary Prevention of Coronary Artery Disease
    Ujjawal, Aditi
    Gupta, Manasvi
    Ghosh, Raktim K.
    Jain, Vardhmaan
    Bandyopadhyay, Dhrubajyoti
    Qamar, Arman
    Aronow, Wilbert S.
    Deedwania, Prakash
    Kapadia, Samir
    Lavie, Carl J.
    [J]. CURRENT PROBLEMS IN CARDIOLOGY, 2021, 46 (03)
  • [8] ASPIRIN FOR PRIMARY PREVENTION OF CORONARY-DISEASE
    FUSTER, V
    CHESEBRO, JH
    [J]. EUROPEAN HEART JOURNAL, 1995, 16 : 16 - 20
  • [9] PHYSICIANS HEALTH STUDY - ASPIRIN AND PRIMARY PREVENTION OF CORONARY HEART-DISEASE
    TAYLOR, DW
    BARNETT, HJM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (26): : 1827 - 1827
  • [10] Aspirin in primary prevention of iscemic heart disease
    Preobrazhensky, DV
    Sidorenko, BA
    Malysheva, NV
    Trushko, VV
    [J]. KARDIOLOGIYA, 2002, 42 (04) : 91 - 95